Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

The FDA approved use of the Atalante X robotic exoskeleton, which allows people with mobility issues to stand upright, for MS ...

—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...

Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

“Identifying the causes and risk factors of MS and substantiating the effectiveness of certain interventions are both crucial ...

Doctors are looking to recruit more people for the trial, which they say could one day be given as a single one-off treatment ...

Advances being used to treat cancer are now being applied to lupus, rheumatoid arthritis, and other disorders.

A new study found smoking cannabis reduced spasticity in MS patients. May 14, 2012— -- Smoking marijuana may reduce certain symptoms in patients with multiple sclerosis, according to a new small ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Read more in the PNW Health series. For decades, when someone in Washington state had to manage multiple sclerosis, care quality often depended on where that person lived. Rural Washingtonians ...